醋酸甲羟孕酮(Medroxyprogesterone Acetate) - 药物靶点：PR_在研适应症：抑制排卵，疼痛，避孕_专利_临床

概要

基本信息

药物类型

小分子化药

别名

(6α)-17-(Acetyloxy)-6-methylpreg-4-ene-3,20-dione、17-Acetoxy-6α-methylprogesterone、17α-hydroxy-6α-methylprogesterone acetate

+ [36]

靶点

PR

作用方式

激动剂

作用机制

PR激动剂(孕激素受体激动剂)

治疗领域

肿瘤神经系统疾病皮肤和肌肉骨骼疾病+ [2]

在研适应症

抑制排卵疼痛避孕+ [14]

非在研适应症

特应性皮炎湿疹神经性皮炎+ [1]

原研机构

Pfizer Inc.

在研机构

Kyowa Kirin Co., Ltd.

Pfizer Japan, Inc.

Pfizer Inc.

+ [1]

非在研机构

天津药物研究院药业有限责任公司Wyeth AB

权益机构

Incepta Pharmaceuticals Ltd.

Strides Pharma Science Ltd.

最高研发阶段批准上市

首次获批日期

美国 (1959-06-18),

闭经子宫内膜增生子宫不规则出血

最高研发阶段(中国)批准上市

特殊审评孤儿药 (美国)

登录后查看时间轴

结构/序列

分子式C22H32O3

InChIKeyFRQMUZJSZHZSGN-HBNHAYAOSA-N

CAS号520-85-4

关联

177

项与醋酸甲羟孕酮相关的临床试验

NCT06979596

/ Recruiting临床2期

A Multicenter, Open-label, Phase 2 Basket Study of MK-5684 in Participants With Selected Solid Tumors (OMAHA-015)

Researchers want to learn if MK-5684 (the study medicine) can treat breast cancer, ovarian cancer, and endometrial cancer. MK-5684, the study medicine, is designed to treat cancer by blocking the body from making steroid hormones.
Researchers will compare MK-5684 to the standard treatments for each cancer type in this study.
The goal of this study is to learn if people who receive MK-5684 live longer without the cancer growing or spreading compared to people who receive a standard treatment.

开始日期2025-08-11

申办/合作机构

Merck Sharp & Dohme LLC

NCT07124195

/ Not yet recruiting临床3期IIT

A Randomized, Controlled, Multicenter Clinical Study on the Whole-Process Management of Nanocrystalline Megestrol in Preventing Chemotherapy-Induced Nausea and Vomiting

The goal of this clinical trial is to learn if medroxyprogesterone acetate oral suspension (Meishiya®) works to prevent nausea and vomiting caused by single-day moderate to high emetogenic chemotherapy (MEC/HEC) in the whole-process management. It will also learn about the safety of medroxyprogesterone acetate oral suspension (Meishiya®). The main questions it aims to answer are:
Does medroxyprogesterone acetate oral suspension (Meishiya®) effectively prevent nausea and vomiting induced by single-day MEC/HEC in the whole-process management? What medical problems do participants have when taking medroxyprogesterone acetate oral suspension (Meishiya®)? Researchers will adopt a multicenter, randomized controlled, open-label trial design and compare the effects of medroxyprogesterone acetate oral suspension (Meishiya®) in preventing chemotherapy-induced nausea and vomiting.
Participants will be:
Stratified based on chemotherapy regimens (HEC vs MEC), gender (male vs female), and age (<55 years vs ≥55 years) Planned to be 126 subjects who are first-time recipients of single-day MEC/HEC for malignant solid tumors Take medroxyprogesterone acetate oral suspension (Meishiya®) as per the study protocol during the chemotherapy period Visit the research centers at specified intervals for checkups and assessments Record details of nausea, vomiting episodes, and any adverse reactions in a diary

开始日期2025-08-10

申办/合作机构

The First Affiliated Hospital of Xinxiang Medical College

NCT06665997

/ Recruiting临床4期IIT

Clinical and Biomarker Effects of Depot Medroxyprogesterone Acetate in Females With Sickle Cell Disease

This research is being conducted to see if using an injectable contraception, Depot Medroxyprogesterone Acetate (Depo-Provera), can reduce the pain experienced by women with sickle cell disease.
Participants in this study will be adult women with sickle cell disease who regularly experience sickle cell pain. They will complete a 3-month "baseline "with no use of hormonal contraception, and then a 3-month follow-up after receiving an injection of Depo-Provera. Participants will complete 6 to 7 in-person visits with a urine pregnancy test, blood draw, and surveys, as well as complete remote weekly surveys and monthly home pregnancy tests.

开始日期2025-06-26

申办/合作机构

University of Pennsylvania

[+3]

100 项与醋酸甲羟孕酮相关的临床结果

登录后查看更多信息

100 项与醋酸甲羟孕酮相关的转化医学

登录后查看更多信息

100 项与醋酸甲羟孕酮相关的专利（医药）

登录后查看更多信息

7,634

项与醋酸甲羟孕酮相关的文献（医药）

2025-12-31·GYNECOLOGICAL ENDOCRINOLOGY

Hormone therapy with different administration routes for patients with perimenopausal syndrome: a systematic review and network meta-analysis

Review

作者: Ren, Mulan ; Luo, Xinrui ; Wang, Liping ; Wang, Yan

PURPOSE:

To comprehensively compare and rank hormone therapy for patients with perimenopausal syndrome.

METHODS:

A comprehensive search was conducted on PubMed, Embase, Cochrane Library, Web of Science, CNKI, VIP, and Wanfang databases from inception to August 20, 2024. The quality of the included randomized controlled trials (RCTs) were measured by the Cochrane risk of bias tool. The Grading of Recommendations Assessment, Development and Evaluation (GRADE) method was applied to grade the quality of evidence in this network meta-analysis. Network plots were depicted to show direct and indirect comparisons of hormone therapy for each outcome. The influences of different hormone therapy on the outcomes were illustrated via forest plots and league tables. Rank probabilities showed the ranking of different administration routes.

RESULTS:

Seven studies involving 704 perimenopausal syndrome patients were included. The rank probabilities suggested that oral estradiol (E₂₎ combined with medroxyprogesterone and general health guidance had the highest likelihood to be the optimal therapy for the severity of menopausal syndrome. General health guidance combined with oral E₂ was less likely to have a nausea and vomiting, and breast pain.

CONCLUSION:

Oral E₂ and medroxyprogesterone or general health guidance combined with oral E₂ may be the effective and safe option for the management of perimenopausal syndrome.

2025-12-01·Current Atherosclerosis Reports

Cardiovascular Risk Associated with Menopause and Menopause Hormone Therapy: A Review and Contemporary Approach to Risk Assessment

Review

作者: Watson, Karol E ; Spertus, Emily ; Press, Marcella Calfon ; D'Costa, Zoee ; Shah, Janki ; Hingorany, Shipra ; Jafari, Lua ; Horwich, Tamara ; Patil, Rajita

Abstract:

Purpose of Review:

Discuss the effects of menopause and menopause hormone therapy (MHT) on cardiovascular risk, and propose a structured, person-centered framework for cardiovascular risk assessment when initiating MHT.

Recent Findings:

The risk of atherosclerotic heart disease accelerates during the menopause transition due to hormonal, metabolic, and vascular changes. Both menopause and MHT affect cardiovascular risk factors (i.e. blood pressure, lipids, insulin resistance) and cardiovascular events (i.e. myocardial infarction and stroke). Early clinical trial evidence demonstrated that oral synthetic MHT, including conjugated equine estrogen (CEE) with medroxyprogesterone acetate (MPA), is associated with increased coronary heart disease and stroke risk, particularly in older, postmenopausal women. Contemporary formulations such as low-dose transdermal estrogen and micronized progesterone have lower cardiovascular risk. A personalized assessment when initiating MHT should consider age, time since menopause, baseline cardiovascular (CV) risk, and choice of MHT formulation. Assessment of baseline CV risk should include a comprehensive review of traditional CV risk factors and consideration of risk-enhancing factors (including female-specific risk factors) and imaging for subclinical atherosclerosis (i.e. coronary artery calcium scoring) to provide a person-centered risk assessment.

Summary:

Menopause is an important period to implement prevention strategies to reduce future incidence CVD. A structured, individualized approach that accounts for the timing, formulation and delivery of MHT can optimize cardiovascular safety. This review provides a framework for personalized decision-making and highlights the need for further research to clarify MHT’s impact on long-term CV outcomes.

Graphical Abstract:

2025-11-11·ONCOGENE

FOXA2 sensitizes endometrial carcinoma to progestin-mediated conservative therapy by triggering PR transcriptional activation

Article

作者: Ning, Jingyuan ; Wang, Yiqin ; Zhou, Jingyi ; He, Xiangjun ; Wang, Jianliu ; Liu, Jie ; Wang, Donglai

Progesterone receptor (PR) expression correlates strongly with progestin sensitivity in fertility-sparing therapy for endometrial carcinoma (EC). However, the mechanisms governing PR expression remain incompletely defined. Here, by stratifying EC patients into PR-high and PR-low groups, we observe that PR-low tumors exhibit enhanced invasion and metastasis signatures, whereas PR-high tumors display increased fatty acid metabolism. Through integrated network analysis, transcriptional correlation across multiple cohorts, and single-cell transcriptomic profiling, FOXA2 is identified as a master regulator of PR expression. Specifically, FOXA2 directly binds the PR promoter, which, in turn, transcriptionally activates PR expression and increases the sensitivity of EC cells to medroxyprogesterone acetate (MPA), an oral progestin used in clinical. Overexpression of FOXA2 markedly inhibits tumor progression, evidenced with reduced cell proliferation and migration while elevated apoptosis. Moreover, FOXA2 is critically involved in lipid metabolic modulation and the administration of Orlistat, an FDA-approval inhibitor of fatty acid synthase, elevates FOXA2 and PR expression, subsequently enhancing progestin sensitivity both in vitro and in vivo. Collectively, our findings identify FOXA2 as a key regulator in controlling PR levels in EC cells and propose the activation of FOXA2-PR axis via Orlistat treatment as a promising therapeutic strategy to improve progestin responsiveness in EC patients.

47

项与醋酸甲羟孕酮相关的新闻（医药）

2025-10-21

·ETPharma

Strides to market Incepta’ contraceptive generic in Africa

New Delhi: Strides Pharma through its step-down wholly owned subsidiary has announced to market Incepta Pharmaceuticals WHO-prequalified contraceptive generic in Africa . The generic version, branded as ' Medogen SubQ ,' is equivalent to Pfizer’s subcutaneous depot medroxyprogesterone acetate (DMPA-SC), a three-month contraceptive that can be administered by healthcare workers or self-injected after appropriate training. Bangladesh-based Incepta Pharmaceuticals developed the therapy with support from the Children’s Investment Fund Foundation (CIFF) and the Gates Foundation . With this collaboration, Strides expands its Women’s Health franchise in Africa, augmenting its existing portfolio of strong brands like Vitafer, L-Gest, and many others. said Aditya Kumar , Executive Director, Business Development, Strides Pharma. “We are very excited to partner with Incepta to make available a version of this easy-to-use, long-acting reversible contraceptive, empowering women in the region to have greater control of their reproductive rights and choices,” he added. By Online Bureau ,

上市批准

2025-10-02

·医药速览

辉瑞将面临一场官司，上千名女性指控其服用避孕药后患有脑瘤

据Herald Sun报道，辉瑞公司面临 1,000 多名女性提起诉讼，指控其在服用避孕药Depo-Provera 后患有脑瘤。狄波-普维拉（Depo-Provera）是一种长效避孕注射剂，在全球范围内被数百万女性使用，已在60多个国家获批使用超过30年，被誉为一种安全有效的治疗选择。该药物通过抑制排卵发挥作用，每三个月注射一次，同时也被用于治疗子宫内膜异位症等月经失调症。在美国，辉瑞正面临一场诉讼，目前代表超过1000名（截至上周已超过1300名）声称因服用该避孕针而患上脑瘤的女性。该案的潜在索赔价值可能高达数十亿美元。辉瑞将出席在佛罗里达州彭萨科拉联邦法院举行的关键听证会，以决定此案是否可以继续进行。原告指控辉瑞未能就长期服用避孕药增加患脑瘤的风险向患者和医生发出警告。而辉瑞则试图驳回案件，其核心辩护是“优先管辖权”（pre-emption）：由于美国食品药品监督管理局曾拒绝了拟议的标签修改，因此根据联邦法律，公司可免除州法院的责任。原告方律师则反驳称，辉瑞在提交标签申请时“歪曲或隐瞒了关键证据”，从而使得“优先管辖权”的辩护站不住脚。早在2024年3月发表在英国医学杂志上的一项基于法国国家健康数据的广泛研究分析发现，使用狄波-普维拉等长效避孕药超过一年的女性，患上脑膜瘤的风险增加了五到六倍。虽然脑膜瘤是非恶性的，但在年龄超过65岁的女性中发病率急剧上升，在35岁以下女性中则较为罕见。由于狄波-普维拉在全球拥有7400万用户，研究作者指出，可归因于该药物的脑膜瘤病例数可能潜在地很高。在澳大利亚，Shine Lawyers正在调查一项潜在的集体诉讼，此前他们已收到近2000名澳大利亚女性的报告，称在使用狄波-普维拉后被诊断出患有至少一种脑膜瘤。预计该索赔可能在未来几个月内提起。澳大利亚女性此前曾对未获得关于长期使用该药可能带来的健康风险（包括骨质疏松和脑膜瘤）的充分警告表示担忧。针对这一风险，英国药品监管机构于去年更新了狄波-普维拉的警告标签，纳入了脑膜瘤风险。澳大利亚的治疗用品管理局（TGA）也证实，在辉瑞澳大利亚提交变更后，已于2024年2月批准将脑膜瘤作为狄波-普维拉的警告之一。 TGA明确指出，如果诊断出脑膜瘤，应停用该药物。尽管TGA在2024年3月更新的消费者用药信息（CMI）中没有明确提到“脑膜瘤”的名称，但其中包含了患者如果出现头痛、听力损失、癫痫发作、瘫痪等症状（即脑膜瘤的症状）应采取行动的信息。辉瑞及其监管机构强调，该药物的长期安全性得到了认可，并指出脑膜瘤是罕见的，尤其是在35岁以下的女性中。辉瑞澳大利亚发言人也强调，公司将患者安全置于首位，并持续与全球卫生当局合作，对所有药物进行严格和持续的监测。推文用于传递知识，如因版权等有疑问，请于本文刊发30日内联系医药速览。原创内容未经授权，禁止转载至其他平台。 ©2021 医药速览保留所有权利往期链接 “小小疫苗”养成记 | 医药公司管线盘点人人学懂免疫学| 人人学懂免疫学（语音版）综述文章解读 | 文献略读 | 医学科普|医药前沿笔记 PROTAC技术| 抗体药物| 抗体药物偶联-ADC 核酸疫苗 | CAR技术| 化学生物学温馨提示医药速览公众号目前已经有近12个交流群（好学，有趣且奔波于医药圈人才聚集于此）。进群请扫描上方二维码，备注“姓名/昵称-企业/高校-具体研究领域/专业”，此群仅为科研交流群，非诚勿扰。简单操作即可星标⭐️医药速览，第一时间收到我们的推送 ①点击标题下方“医药速览” ②至右上角“...” ③点击“设为星标

2025-09-12

·EINPresswire

Depo-Provera Safety Questioned as Studies Explore Meningioma Risk

Evidence indicates that Depo-Provera can cause specific mutations in women's DNA. Given the availability of alternatives without this known risk, the continued use of the shot difficult to justify.” — Greg Vigna, MD, JD LOS ANGELES, CA, UNITED STATES, September 12, 2025 / EINPresswire.com / -- “ACOG is not recommending a ban on Depo-Provera, despite evidence linking it to a specific mutation associated with meningiomas that are more likely to be multiple and located at the skull base,” states Greg Vigna, MD, JD , national malpractice, Depo-Provera attorney. Read what the American College of Obstetricians and Gynecologist (ACOG) says about Depo-Provera: https://www.acog.org/clinical-information/patient-education-materials/tools-for-navigating-discussions/counseling-guides/birth-control-injection Greg Vigna, MD, JD, national malpractice attorney, states, “We are looking at recurrent meningiomas in patients with ongoing use of Depo-Provera, including continued use after 2021, which may present a source of liability for prescribers." What does Dr. Tessa Harland report in “Progesterone-only contraception is associated with a shorter progression-free survival in premenopausal women with WHO Grade I meningioma” published in the Journal of Neurooncology (2018) 136:327-333? "Compared to patients taking combination or estrogen-only contraception, those taking progesterone-only contraception demonstrated a greater recurrence rate (33.3 vs. 19.6%) with a reduced time to recurrence (18 vs. 32 months, p = 0.038) … those taking progesterone-only contraception.” Read Dr. Harland’s article: https://link.springer.com/article/10.1007/s11060-017-2656-9 What did Dr. Peyre report in “Progestin-associated shift of meningioma mutational landscape” published in Annals of Oncology. Vol. 29, Issue 3, March 2018, Pg. 681-686? “The main result of our study is the increased frequency of PIK3CA mutations (35%) in progestin-associated meningiomas compared with the control population. This shift in mutational landscape indicates the vulnerability of certain meningeal cells and mutations to hormone-induced tumorigenesis. Progestin-associated meningiomas were more frequently multiple meningiomas and located at the skull base.” Read Dr. Peyre’s article: https://www.sciencedirect.com/science/article/pii/S0923753419354882 Dr. Vigna concludes, “There are safer contraceptive alternatives available. Evidence indicates that Depo-Provera can cause specific mutations in women's DNA. Given the availability of alternatives without this known risk, the continued use of the shot difficult to justify." Watch Dr. Vigna’s educational episode on Justice with Dr. V for an in-depth look at the association of Depo-Provera and meningiomas: https://youtu.be/08n0qssgZfUsi=TtebqjOM6qgHvGCK Dr. Vigna is a California and Washington DC lawyer and is co-counsel with the Ben Martin Law Group , a national pharmaceutical injury law firm in Dallas, Texas. The attorneys are product liability and medical malpractice attorneys, and they represent women who have suffered meningiomas. To learn more about Depo-Provera and meningiomas, click here . California Offices: 8939 S. Sepulveda Blvd., Suite 102, Los Angeles, CA 90045 2570 N. First Street, 2nd Floor, San Jose, CA 95131 931 10th Street, #962, Modesto, CA 95354 2281 Lava Ridge Court, Suite 200, Roseville, CA 95661 600 West Broadway, Suite 700, San Diego, CA 92101 Connecticut Office: 515 Centerpoint Drive, Suite #2212, Middletown, CT 06457 Greg Vigna, MD, JD Vigna Law Group +1 817-809-9023 email us here Visit us on social media: LinkedIn Facebook X Legal Disclaimer: EIN Presswire provides this news content "as is" without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author above.

临床研究

100 项与醋酸甲羟孕酮相关的药物交易

登录后查看更多信息

外链

KEGG	Wiki	ATC	Drug Bank
D00951	醋酸甲羟孕酮	L02AB02 G03AC06 G03DA02	DB00603

研发状态

批准上市

10 条最早获批的记录,

登录

后查看更多信息

适应症	国家/地区	公司	日期
抑制排卵	日本	Kyowa Kirin Co., Ltd.	2022-03-11
疼痛	美国	Pfizer Inc.	2020-12-04
避孕	美国	Pfizer Inc.	2004-12-17
怀孕	美国	Pfizer Inc.	1992-10-29
乳腺癌	中国	西安利君制药有限责任公司	1982-01-01
子宫内膜癌	中国	西安利君制药有限责任公司	1982-01-01
前列腺癌	中国	西安利君制药有限责任公司	1982-01-01
肾细胞癌	中国	西安利君制药有限责任公司	1982-01-01
习惯性流产	日本	Pfizer Japan, Inc.	1963-01-25
先兆流产	日本	Pfizer Japan, Inc.	1963-01-25
月经过少	日本	Pfizer Japan, Inc.	1963-01-25
不孕	日本	Pfizer Japan, Inc.	1963-01-25
月经过多	日本	Pfizer Japan, Inc.	1963-01-25
月经紊乱	日本	Pfizer Japan, Inc.	1963-01-25
闭经	美国	Pfizer Inc.	1959-06-18
子宫内膜增生	美国	Pfizer Inc.	1959-06-18
子宫不规则出血	美国	Pfizer Inc.	1959-06-18

未上市

10 条进展最快的记录,

登录

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
特应性皮炎	临床3期	中国	天津药物研究院药业有限责任公司	2019-12-11
湿疹	临床3期	中国	天津药物研究院药业有限责任公司	2019-12-11
神经性皮炎	临床3期	中国	天津药物研究院药业有限责任公司	2019-12-11
绝经期后骨质疏松	临床1期	-	Wyeth AB	2006-09-01

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


NCT04669678 (EPIC, CTgov)	临床4期	药物相互作用 \| HIV感染 \| 避孕	110	Etonogestrel (Group 1 DOR + ETG)	餘艱觸選襯窪網夢觸淵(築淵鏇膚餘鏇觸鏇窪獵) = 範簾夢築顧廠選襯網願廠艱願網觸製膚醖鑰醖 (願鹽觸築廠餘餘積衊糧, 艱壓廠顧遞鹹糧鑰獵築 ~ 積艱觸鑰願鬱衊廠壓醖) 更多	-	2025-04-08
				Intramuscular depo-medroxyprogesterone acetate (IM DMPA) (Group 2 DOR + IM DMPA)	餘艱觸選襯窪網夢觸淵(築淵鏇膚餘鏇觸鏇窪獵) = 觸鹽壓願顧構醖繭餘觸廠艱願網觸製膚醖鑰醖 (願鹽觸築廠餘餘積衊糧, 壓選艱鹽蓋窪壓積鏇選 ~ 構壓顧獵鑰構繭繭醖遞) 更多
NCMP-03 (SNO2024)	N/A	脑膜瘤 ER/PR	64	EstrogenroneProgesteroneon (Estrogen or Progesterone use)	願願選糧範鑰獵獵鹹廠(範鏇餘遞鏇廠遞構鹹製) = 廠網艱醖鬱範製蓋廠繭簾壓網構襯膚襯廠鏇餘 (鹹廠夢選遞顧襯餘製壓 )	积极	2024-11-11
				ProgesteroProgesteronetion (Unopposed Progesterone only use)	願願選糧範鑰獵獵鹹廠(範鏇餘遞鏇廠遞構鹹製) = 觸積廠願餘選構獵鏇繭簾壓網構襯膚襯廠鏇餘 (鹹廠夢選遞顧襯餘製壓 )
ASTRO2024	N/A	脑膜瘤	-	Progesterone use	衊廠選膚憲齋膚繭淵築(襯醖鬱觸淵窪壓鬱淵窪) = 齋鹽衊窪簾廠齋築襯獵鬱鹹鏇糧網築夢簾鹽築 (觸廠簾齋糧窪顧廠築鑰 )	-	2024-10-01
				Estrogenroneprogesteroneon (Estrogen or progesterone use)	衊廠選膚憲齋膚繭淵築(襯醖鬱觸淵窪壓鬱淵窪) = 艱鹹壓範壓齋衊膚繭觸鬱鹹鏇糧網築夢簾鹽築 (觸廠簾齋糧窪顧廠築鑰 )
NCT02550067 (ECHO, Pubmed \| BMC Womens Health) 人工标引	N/A	避孕	398	Depot medroxyprogesterone acetate (DMPA-IM)	製網襯築壓齋壓廠壓淵(獵鏇網遞蓋鹽膚鏇膚觸) = 衊鬱鑰範衊餘夢艱鑰獵膚襯淵鹹獵鑰簾積糧範 (積夢觸淵膚網膚醖製襯 ) 更多	积极	2024-03-08
				copper intrauterine device	製網襯築壓齋壓廠壓淵(獵鏇網遞蓋鹽膚鏇膚觸) = 餘餘鹹鬱願淵鏇廠淵製膚襯淵鹹獵鑰簾積糧範 (積夢觸淵膚網膚醖製襯 ) 更多
FRI413 (ENDO2023)	N/A	闭塞	84	Norethisterone	壓獵構襯積構簾顧構窪(鹹餘繭蓋糧衊選獵網艱) = 網蓋顧繭艱廠選製積膚築膚餘糧夢壓襯簾齋遞 (鹽憲衊鬱餘窪構餘廠鹽, 0 ~ 252)	-	2023-10-05
NCT05438277 (CTgov)	临床4期	肩痛	421	MPA+Methylprednisolone (Methylprednisolone Acetate (MPA))	衊鑰簾壓襯獵積膚簾觸 = 鹽願鑰遞齋窪廠憲淵鬱簾壓壓壓鬱製餘夢鹽憲 (糧觸構廠獵鏇餘鬱願鏇, 遞簾選鬱網衊衊觸構糧 ~ 範憲鑰製鬱夢範鹽遞廠) 更多	-	2023-03-07
				Triamcinolone Acetonide (TA) (Triamcinolone Acetonide (TA))	衊鑰簾壓襯獵積膚簾觸 = 襯淵簾醖餘獵艱蓋選選簾壓壓壓鬱製餘夢鹽憲 (糧觸構廠獵鏇餘鬱願鏇, 鬱齋鏇齋衊壓淵鑰鬱築 ~ 憲糧繭鑰襯選壓鑰顧齋) 更多
NCT02550067 (Pubmed \| Clin Infect Dis)	N/A	单纯疱疹	4,062	Depot medroxyprogesterone acetate (DMPA-IM)	窪齋顧淵窪簾廠願築鏇(構憲衊膚糧襯積遞糧築) = 廠糧製製觸鹹築窪夢構壓餘夢鏇壓網積積淵鑰 (鹽觸製艱鹽餘觸窪範鏇 )	-	2022-09-10
				Levonorgestrel (LNG) implant	窪齋顧淵窪簾廠願築鏇(構憲衊膚糧襯積遞糧築) = 簾製鏇觸鹽憲夢淵簾製壓餘夢鏇壓網積積淵鑰 (鹽觸製艱鹽餘觸窪範鏇 )
SGO2022	N/A	子宫内膜癌	-	Progestin retreatment	醖襯顧簾顧顧獵繭衊顧(廠鬱鏇鬱繭顧窪衊膚積) = 鑰築壓糧醖遞壓醖糧獵餘顧夢膚衊窪醖簾遞獵 (壓築蓋廠範憲膚願夢製 ) 更多	-	2022-08-01
NCT02122198 (CTgov)	N/A	认知功能障碍 \| 内皮功能障碍 \| 执行功能受损	17	Placebo (Placebo)	願醖夢壓襯繭觸簾範製(糧壓鏇獵衊鏇鬱範鹹艱) = 繭襯艱鹽餘願憲衊繭積鏇襯積鏇鹽夢構衊積襯 (鹹獵鑰餘衊蓋襯艱膚遞, 3.88) 更多	-	2022-01-10
				Medroxyprogesterone+Estradiol+Leuprolide acetate (GnRH Agonist)	願醖夢壓襯繭觸簾範製(糧壓鏇獵衊鏇鬱範鹹艱) = 製獵願膚鏇蓋繭蓋襯鹹鏇襯積鏇鹽夢構衊積襯 (鹹獵鑰餘衊蓋襯艱膚遞, 57.61) 更多
NCT02550067 (ECHO, Pubmed)	N/A	-	401	Depot Medroxyprogesterone Acetate Intramuscular Injection	壓齋積構廠鹹窪廠範蓋(襯鏇積範選獵齋艱鬱選) = 壓範淵憲願窪構積醖鏇製顧築壓膚構範壓鏇鬱 (壓憲製蓋遞鏇窪齋蓋醖 )	-	2022-01-01
				Copper Intrauterine Device	壓齋積構廠鹹窪廠範蓋(襯鏇積範選獵齋艱鬱選) = 蓋範壓製鹹糧積壓鏇選製顧築壓膚構範壓鏇鬱 (壓憲製蓋遞鏇窪齋蓋醖 )